netakimab vs vunakizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriatic Arthritis
Shared mechanism: IL-17 · full Psoriatic Arthritis pipeline
netakimab
Marketed by Biocad
NCT03598751 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 194 patients. The proportion of patients achieving a validated joint-response measure (ACR20) was overwhelmingly higher with netakimab than placebo, a gap large enough to leave no real doubt about the direction of the effect even though a formal statistical test was not reported in the source used.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
ACR 20 (week 24): ACR20 response at week 24: 82% (80/97) netakimab vs 9% (9/97) placebo. (met)
Result source: NCT03598751
vunakizumab
Marketed by Jiangsu Hengrui Pharmaceuticals
NCT05055934 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 112 participants, using the clinical ACR20 improvement measure as its primary endpoint. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.
Reported efficacy
Proportion of subjects achieving ACR 20 improvement at week 12: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively (met)
Result source: NCT05055934
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | netakimab | vunakizumab |
|---|---|---|
| ACR20 | 82% vs 9%a+73 vs placeboNCT03598751 | —Trial running · NCT06640257 |
| ACR50 | —Not posted · NCT03598751 | —Trial running · NCT06640257 |
| PASI 75 | —Not posted · NCT03598751 | —Trial running · NCT06640257 |
| Minimal disease activity | —Not posted · NCT03598751 | —Trial running · NCT06640257 |
| HAQ-DI, change | —Not posted · NCT03598751 | —Trial running · NCT06640257 |
ACR20
- netakimab
- 82% vs 9%a+73 vs placeboNCT03598751
- vunakizumab
- —Trial running · NCT06640257
ACR50
- netakimab
- —Not posted · NCT03598751
- vunakizumab
- —Trial running · NCT06640257
PASI 75
- netakimab
- —Not posted · NCT03598751
- vunakizumab
- —Trial running · NCT06640257
Minimal disease activity
- netakimab
- —Not posted · NCT03598751
- vunakizumab
- —Trial running · NCT06640257
HAQ-DI, change
- netakimab
- —Not posted · NCT03598751
- vunakizumab
- —Trial running · NCT06640257
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
netakimab
Psoriasis
Shared mechanism: IL-17 · full Psoriasis pipeline
netakimab
Marketed by Biocad
NCT03390101 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 213 participants and a clinical psoriasis endpoint (PASI 75) assessed at week 12. Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.
Reported efficacy
• The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment: • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment (week 12): BCD-085 Q2W 66/85 (77.6%) | BCD-085 Q4W 70/84 (83.3%) vs Placebo 0/44 (0.0%) (met)
Result source: NCT03390101
vunakizumab
Marketed by Jiangsu Hengrui Pharmaceuticals
NCT04839016 · Phase 3 · status unknown
This randomized, double-blind, placebo-controlled Phase 3 trial randomized 690 patients with moderate-to-severe plaque psoriasis 2:1 to vunakizumab 240 mg or placebo. The co-primary endpoints were PASI 90 and sPGA 0/1 at week 12. PASI 90 was reached by 76.8% of patients on vunakizumab and 0.9% on placebo, and sPGA 0/1 by 71.8% and 0.4% (both two-sided P < .0001), so both co-primary endpoints were met. The registry record still shows its 2021 estimated enrollment of 660 and has no posted results; the figures come from the peer-reviewed paper (Yan et al., J Am Acad Dermatol 2025).
Caveat: this result is taken from the peer-reviewed paper (Yan et al., J Am Acad Dermatol 2025, PMID 39332633); the ClinicalTrials.gov record (status unknown) has no posted results.
Next expected readout: March 2027 · NCT06779097 (registry estimate)
Reported efficacy
Percentage of subjects who achieve at least 90% improvement in PASI score (PASI 90) at Week 12; sPGA of 0 or 1 response at Week 12: Week 12 co-primary endpoints, vunakizumab 240 mg vs placebo (690 randomized 2:1): PASI 90 76.8% vs 0.9%; sPGA 0/1 71.8% vs 0.4%; both two-sided P < .0001 (Yan et al., J Am Acad Dermatol 2025). (met)
Result source: NCT04839016
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | netakimab | vunakizumab |
|---|---|---|
| PASI 75 | 77.6% vs 0%+77.6 vs placeboNCT033901014 other results
| —Trial running · NCT06833307 |
| PASI 90 | —Not posted · NCT07008547 | —Trial running · NCT06833307 |
| PASI 100 | —Not posted · NCT07008547 | —Trial running · NCT06833307 |
| sPGA 0/1 | —Not posted · NCT07008547 | —Trial running · NCT06833307 |
| DLQI, change | —Not posted · NCT07008547 | —Trial running · NCT06833307 |
PASI 75
- netakimab
- 77.6% vs 0%+77.6 vs placeboNCT03390101
4 other results
- 83.3% vs 0% NCT03390101
- 92.9% vs 23.1% NCT02762994
- 83.3% vs 23.1% NCT02762994
- 80% vs 23.1% NCT02762994
- vunakizumab
- —Trial running · NCT06833307
PASI 90
- netakimab
- —Not posted · NCT07008547
- vunakizumab
- —Trial running · NCT06833307
PASI 100
- netakimab
- —Not posted · NCT07008547
- vunakizumab
- —Trial running · NCT06833307
sPGA 0/1
- netakimab
- —Not posted · NCT07008547
- vunakizumab
- —Trial running · NCT06833307
DLQI, change
- netakimab
- —Not posted · NCT07008547
- vunakizumab
- —Trial running · NCT06833307
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. netakimab: 3 of 4 rows · vunakizumab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | netakimab |
|---|---|
| Dropout rate | 0%Q2Wa NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 show 4 more results2.4%Q4W NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 6.7%120 mg NCT02762994 · Phase 2 · registry result, not featured evidence 3.2%80 mg NCT02762994 · Phase 2 · registry result, not featured evidence 3.2%40 mg NCT02762994 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —Q2Wa NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 show 4 more results—Q4W NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 —120 mg NCT02762994 · Phase 2 · registry result, not featured evidence —80 mg NCT02762994 · Phase 2 · registry result, not featured evidence —40 mg NCT02762994 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%Q2Wa NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 show 4 more results1.2%Q4W NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 0%120 mg NCT02762994 · Phase 2 · registry result, not featured evidence 0%80 mg NCT02762994 · Phase 2 · registry result, not featured evidence 0%40 mg NCT02762994 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | Q2Wa hyperbilirubinemia 4.7% (placebo 2.3%) neutropenia 3.5% (placebo 0%) alanine aminotransferase increased 1.2% (placebo 0%) NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 show 4 more resultsQ4W hyperglycaemia 3.6% (placebo 0%) hyperbilirubinemia 2.4% (placebo 2.3%) leukopenia 2.4% (placebo 0%) NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 120 mg arterial bp increased 10.7% (placebo 0%) arvi 3.6% (placebo 3.6%) flu-like symptoms 3.6% (placebo 0%) NCT02762994 · Phase 2 · registry result, not featured evidence 80 mg ggt increased 10% (placebo 7.1%) arterial bp increased 6.7% (placebo 0%) neutropenia 6.7% (placebo 3.6%) NCT02762994 · Phase 2 · registry result, not featured evidence 40 mg neutropenia 12.9% (placebo 3.6%) arvi 9.7% (placebo 3.6%) conjuctivitis 3.2% (placebo 0%) NCT02762994 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
netakimab
show 4 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: netakimab's landscape · vunakizumab's landscape